Dare Bioscience, Inc. (DARE) financial statements (2021 and earlier)

Company profile

Business Address 3655 NOBEL DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5555526
Cash and cash equivalents5555526
Receivables0000100
Prepaid expense2124110
Total current assets:7789637
Noncurrent Assets
Property, plant and equipment0000000
Other noncurrent assets1111111
Total noncurrent assets:1111111
TOTAL ASSETS:88910747
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3433201
Accounts payable 222   
Accrued liabilities 222 21
Employee-related liabilities1   1  
Other undisclosed accounts payable and accrued liabilities2   1(1)(1)
Debt00000  
Business combination, contingent consideration, liability11     
Other undisclosed current liabilities3321321
Total current liabilities:8865622
Noncurrent Liabilities
Long-term debt and lease obligation 00    
Operating lease, liability 00    
Liabilities, other than long-term debt1122100
Deferred revenue1111   
Other liabilities0  0000
Business combination, contingent consideration, liability  111  
Total noncurrent liabilities:1122100
Total liabilities:9987722
Stockholders' equity
Stockholders' equity attributable to parent(1)(1)03025
Common stock0000000
Additional paid in capital70625652454242
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(71)(63)(55)(48)(44)(40)(37)
Total stockholders' equity:(1)(1)03025
TOTAL LIABILITIES AND EQUITY:88910747

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(8)(8)(7)(4)(4)(3)(4)
Operating loss:(8)(8)(7)(4)(4)(3)(4)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)00(0)00
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)   (0)  
Net loss:(8)(8)(7)(4)(4)(3)(4)
Other undisclosed net income attributable to parent0   0  
Net loss attributable to parent:(8)(8)(7)(4)(4)(3)(4)
Preferred stock dividends and other adjustments (0)    (1)
Net loss available to common stockholders, diluted:(8)(8)(7)(4)(4)(3)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(8)(8)(7)(4)(4)(3)(4)
Comprehensive loss:(8)(8)(7)(4)(4)(3)(4)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)0(0)0(0)(1)
Comprehensive loss, net of tax, attributable to parent:(8)(8)(7)(4)(4)(3)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: